Bortezomib maintenance (BM) or consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): 8-year follow-up of CALGB 50403 (Alliance)
- Citation:
- Blood vol 132 (suppl 1) 146
- Meeting Instance:
- ASH 2018
- Year:
- 2018
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Long-Term-Followup
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3168
- Pharmas:
- Millennium
- Grants:
- U10CA180821, U10CA180882, U24CA196171
- Corr. Author:
- Authors:
- Lawrence D. Kaplan Matthew Maurer Wendy Stock Noreen Fulton Nancy Bartlett Adam Pettinger John Byrd Kristie A. Blum Anne S. LaCasce Eric D. Hsi David Hurd Amy Ruppert John P. Leonard Bruce. D. Cheson
- Networks:
- CA136, CAPITAL, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-OH007, NC002, NY018, OH070
- Study
- CALGB-50403
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: